1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Assisted Reproductive Technology Market
4. Market Overview
4.1. Introduction
4.1.1. Technology Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Assisted Reproductive Technology Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Technology/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Assisted Reproductive Technology Market Analysis and Forecast, by Technology
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Technology, 2017–2031
6.3.1. In Vitro Fertilization
6.3.1.1. Intra-cytoplasmic Sperm Injection (ICSI)
6.3.1.2. Preimplantation Genetic Diagnosis (PGD)
6.3.2. Artificial Insemination
6.3.2.1. Intrauterine Insemination (IUI)
6.3.2.2. Intracervical Insemination (ICI)
6.3.2.3. Others
6.3.3. Surrogacy
6.3.4. Others
6.4. Market Attractiveness Analysis, by Technology
7. Global Assisted Reproductive Technology Market Analysis and Forecast, by Procedure
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Procedure, 2017–2031
7.3.1. Frozen Donor
7.3.2. Frozen Non-donor
7.3.3. Fresh Donor
7.3.4. Fresh Non-donor
7.3.5. Embryo Banking
7.4. Market Attractiveness Analysis, by Procedure
8. Global Assisted Reproductive Technology Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Fertility Clinics
8.3.2. Hospitals
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Assisted Reproductive Technology Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Assisted Reproductive Technology Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Technology, 2017–2031
10.3.1. In Vitro Fertilization
10.3.1.1. Intra-cytoplasmic Sperm Injection (ICSI)
10.3.1.2. Preimplantation Genetic Diagnosis (PGD)
10.3.2. Artificial Insemination
10.3.2.1. Intrauterine Insemination (IUI)
10.3.2.2. Intracervical Insemination (ICI)
10.3.2.3. Others
10.3.3. Surrogacy
10.3.4. Others
10.4. Market Value Forecast, by Procedure, 2017–2031
10.4.1. Frozen Donor
10.4.2. Frozen Non-donor
10.4.3. Fresh Donor
10.4.4. Fresh Non-donor
10.4.5. Embryo Banking
10.5. Market Value Forecast, by End-user, 2017–2031
10.5.1. Fertility Clinics
10.5.2. Hospitals
10.5.3. Others
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Technology
10.7.2. By Procedure
10.7.3. By End-user
10.7.4. By Country
11. Europe Assisted Reproductive Technology Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Technology, 2017–2031
11.3.1. In Vitro Fertilization
11.3.1.1. Intra-cytoplasmic Sperm Injection (ICSI)
11.3.1.2. Preimplantation Genetic Diagnosis (PGD)
11.3.2. Artificial Insemination
11.3.2.1. Intrauterine Insemination (IUI)
11.3.2.2. Intracervical Insemination (ICI)
11.3.2.3. Others
11.3.3. Surrogacy
11.3.4. Others
11.4. Market Value Forecast, by Procedure, 2017–2031
11.4.1. Frozen Donor
11.4.2. Frozen Non-donor
11.4.3. Fresh Donor
11.4.4. Fresh Non-donor
11.4.5. Embryo Banking
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Fertility Clinics
11.5.2. Hospitals
11.5.3. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Technology
11.7.2. By Procedure
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Assisted Reproductive Technology Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Technology, 2017–2031
12.3.1. In Vitro Fertilization
12.3.1.1. Intra-cytoplasmic Sperm Injection (ICSI)
12.3.1.2. Preimplantation Genetic Diagnosis (PGD)
12.3.2. Artificial Insemination
12.3.2.1. Intrauterine Insemination (IUI)
12.3.2.2. Intracervical Insemination (ICI)
12.3.2.3. Others
12.3.3. Surrogacy
12.3.4. Others
12.4. Market Value Forecast, by Procedure, 2017–2031
12.4.1. Frozen Donor
12.4.2. Frozen Non-donor
12.4.3. Fresh Donor
12.4.4. Fresh Non-donor
12.4.5. Embryo Banking
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Fertility Clinics
12.5.2. Hospitals
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Technology
12.7.2. By Procedure
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Assisted Reproductive Technology Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Technology, 2017–2031
13.3.1. In Vitro Fertilization
13.3.1.1. Intra-cytoplasmic Sperm Injection (ICSI)
13.3.1.2. Preimplantation Genetic Diagnosis (PGD)
13.3.2. Artificial Insemination
13.3.2.1. Intrauterine Insemination (IUI)
13.3.2.2. Intracervical Insemination (ICI)
13.3.2.3. Others
13.3.3. Surrogacy
13.3.4. Others
13.4. Market Value Forecast, by Procedure, 2017–2031
13.4.1. Frozen Donor
13.4.2. Frozen Non-donor
13.4.3. Fresh Donor
13.4.4. Fresh Non-donor
13.4.5. Embryo Banking
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Fertility Clinics
13.5.2. Hospitals
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Technology
13.7.2. By Procedure
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Assisted Reproductive Technology Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Technology, 2017–2031
14.3.1. In Vitro Fertilization
14.3.1.1. Intra-cytoplasmic Sperm Injection (ICSI)
14.3.1.2. Preimplantation Genetic Diagnosis (PGD)
14.3.2. Artificial Insemination
14.3.2.1. Intrauterine Insemination (IUI)
14.3.2.2. Intracervical Insemination (ICI)
14.3.2.3. Others
14.3.3. Surrogacy
14.3.4. Others
14.4. Market Value Forecast, by Procedure, 2017–2031
14.4.1. Frozen Donor
14.4.2. Frozen Non-donor
14.4.3. Fresh Donor
14.4.4. Fresh Non-donor
14.4.5. Embryo Banking
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Fertility Clinics
14.5.2. Hospitals
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Technology
14.7.2. By Procedure
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Merck KGaA
15.3.1.1. Company Overview
15.3.1.2. Technology Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. CooperSurgical, Inc.
15.3.2.1. Company Overview
15.3.2.2. Technology Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. FUJIFILM Irvine Scientific
15.3.3.1. Company Overview
15.3.3.2. Technology Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Vitrolife AB
15.3.4.1. Company Overview
15.3.4.2. Technology Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Hamilton Thorne, Inc.
15.3.5.1. Company Overview
15.3.5.2. Technology Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Nikon Corporation
15.3.6.1. Company Overview
15.3.6.2. Technology Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Nidacon International AB
15.3.7.1. Company Overview
15.3.7.2. Technology Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Laboratoire CCD
15.3.8.1. Company Overview
15.3.8.2. Technology Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Esco Micro Pte. Ltd.
15.3.9.1. Company Overview
15.3.9.2. Technology Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer